-
公开(公告)号：US20240360212A1
公开(公告)日：2024-10-31
申请号：US18766765
申请日：2024-07-09
Applicant: Janssen Biotech, Inc.
Inventor： Bruce Randazzo , Yasmine Wasfi
IPC: C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , A61P17/06
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61P17/06 , C07K16/241 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/56 , C07K2317/565
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
-
公开(公告)号：US11548941B2
公开(公告)日：2023-01-10
申请号：US16688178
申请日：2019-11-19
Applicant: Janssen Biotech, Inc.
Inventor： Julianty Angsana , Patrick Branigan , Samuel DePrimo , Susan Flavin , Shu Li , Xuejun Liu , Ernesto Munoz , Bruce Randazzo
IPC: C07K16/24 , A61K39/395 , A61P17/06 , A61K45/06
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
-
公开(公告)号：US20220289835A1
公开(公告)日：2022-09-15
申请号：US17734482
申请日：2022-05-02
Applicant: Janssen Biotech, Inc.
Inventor： Julianty Angsana , Patrick Branigan , Samuel DePrimo , Susan Flavin , Shu Li , Xeujun Liu , Ernesto Munoz , Bruce Randazzo
IPC: C07K16/24 , A61P17/06 , A61K39/395
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
-
公开(公告)号：US20200157209A1
公开(公告)日：2020-05-21
申请号：US16688178
申请日：2019-11-19
Applicant: Janssen Biotech, Inc.
Inventor： Julianty Angsana , Patrick Branigan , Samuel DePrimo , Susan Flavin , Shu Li , Xuejun Liu , Ernesto Munoz , Bruce Randazzo
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody
-
Patent Agency Ranking
公开(公告)号：US20240101662A1
公开(公告)日：2024-03-28
申请号：US18513931
申请日：2023-11-20
Applicant: Janssen Biotech, Inc.
Inventor： Ming-Chun Hsu , Shu Li , Bruce Randazzo , Kun Song , Yaowei Zhu
CPC classification number: C07K16/244 , A61P17/06 , A61K2039/505
Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
-
公开(公告)号：US20200331996A1
公开(公告)日：2020-10-22
申请号：US16819629
申请日：2020-03-16
Applicant: Janssen Biotech, Inc.
Inventor： Ming-Chun Hsu , Shu Li , Bruce Randazzo , Kun Song , Yaowei Zhu
Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
-
公开(公告)号：US20230014839A1
公开(公告)日：2023-01-19
申请号：US17931633
申请日：2022-09-13
Applicant: Janssen Biotech, Inc.
Inventor： Ming-Chun Hsu , Shu Li , Bruce Randazzo , Kun Song , Yaowei Zhu
Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
-
公开(公告)号：US20220073603A1
公开(公告)日：2022-03-10
申请号：US17389533
申请日：2021-07-30
Applicant: Janssen Biotech, Inc.
Inventor： Ming-Chun Hsu , Shu Li , Bruce Randazzo , Kun Song , Yaowei Zhu
Abstract: Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.
-
公开(公告)号：US20180094052A1
公开(公告)日：2018-04-05
申请号：US15719899
申请日：2017-09-29
Applicant: Janssen Biotech, Inc.
Inventor： Bruce Randazzo , Yasmine Wasfi
IPC: C07K16/24 , A61P17/06 , A61K45/06 , A61K39/395
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P17/06 , C07K16/241 , C07K2317/21 , C07K2317/56 , C07K2317/565
Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
